Vol. 4 No. 6S (2010)

Published: 2010-12-15

Editorial

Nilotinib: selective inhibitor as second-line therapy

Massimo Breccia

3-5
- PDF

Case report

Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Fabio Stagno, Alessandra Cupri, Stefania Stella, Michele Massimino, Silvia Rita Vitale, Paolo Vigneri

7-11
- PDF
Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib

Fausto Palmieri

13-16
- PDF
Nilotinib after imatinib failure

Luca Pezzullo

17-21
- PDF
Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib

Ivana Pierri, Micaela Bergamaschi, Antonia Cagnetta, Anna Ghiso, Marco Gobbi

23-26
- PDF